MHC multimer technology

1 Introduction to antigen-specific T cell biology

1.1 Antigen-specific T cells and their relevance

Antigen-specific T cells are essential effectors of the adaptive immune system, responsible for recognizing and responding to antigens presented by aberrant or infected cells. Through their unique T cell receptors (TCRs), they are capable of discriminating between self and foreign antigens, enabling targeted immune responses against pathogens. Their specificity and ability to remember past infections underpin the effectiveness of immunological memory, which is the basis for vaccination strategies. Antigen-specific T cells are categorized into two subsets based on their coreceptor expression: CD8+ cytotoxic T cells and CD4+ helper T cells. CD8+ T cells are the main effectors of cell-mediated immunity, detecting and killing abnormal cells such as cancer or virus-infected cells. By contrast, CD4+ T cells are responsible for coordinating an efficient immune response against a specific threat or pathogen.

Recent advances in manipulating antigen-specific T cells hold promise for developing novel immunotherapies to treat cancer, infections, and autoimmune diseases. Antigen-specific therapeutic approaches include genetically engineered TCR T cells, designed to specifically target a patient’s cancer cells or to recognize susceptible patterns in pathogenic viruses not detected by the patient’s immune system.

1.2 Antigen recognition and MHC restriction

TCRs can recognize antigens only when these are presented by major histocompatibility complex (MHC) molecules, an immunological principle known as MHC restriction. MHC molecules are loaded with short peptide sequences, or T cell epitopes, derived from processed proteins inside the cell, and then present them to the extracellular space. The interaction of TCRs with MHC-bound peptides is highly specific and relies on the complementary fit between TCR and MHC complex. Every TCR is uniquely restricted to bind only one specific combination of peptide-MHC (pMHC) (fig. 1).

Figure 1: Antigen recognition by T cells

CD8+ and CD4+ T cells recognize specific antigens via their TCRs only when presented by MHC class I or II molecules, respectivelyarrow leftarrow right

TCRs expressed on antigen-specific T cells bind to MHC molecules loaded with peptides (pMHC complex). Short peptide sequences loaded on MHCs are also termed T cell epitopes. The pMHC complexes are presented to the T cells by antigen-presenting cells (APCs).

1.3 MHC and peptide classification

Two important classes of MHC molecules interact with antigen-specific T cells, MHC I and MHC II (table 1). CD8+ T cells recognize MHC class I molecules, expressed on virtually every nucleated cell. Peptides presented on MHC I mainly derive from intracellular proteins, enabling the immune system to monitor intracellular abnormalities like mutations and infections. By contrast, CD4+ T cells bind to MHC class II molecules, expressed only on professional antigen-presenting cells (APCs). MHC II typically presents peptides from extracellular proteins, uncovering foreign pathogens or allergens.

Table 1: Comparison of MHC class I and class II molecules.

 MHC class I MHC class II
Expressed onAll nucleated body cells.Professional APCs, e.g., dendritic cells, macrophages, and B cells.
Length of bound epitope (amino acids)8–1213–25
Main peptide source*Intracellular source, such as:

- Self-peptides;
- Mutated (neo-)antigens;
- Peptides derived from replicating pathogens, such as viruses.
Extracellular source, such as:

- Matrix peptides;
- Bacterial peptides derived from extracellular infections;
- Allergens.
Interacting T cellCD8+ cytotoxicCD4+ helper

* Please note that cross-presentation of MHC I and II peptides is frequently observed.

1.4 MHC genetics and nomenclature

In humans, the MHC locus is known as the human leukocyte antigen (HLA) system, a highly polymorphic genomic region on chromosome 6. Each individual inherits a unique combination of HLA alleles that defines our immunological self (see table 2). This diversity is essential for immune defense and transplantation compatibility.

HLA genes are divided into three classes:

  • Class I (e.g., HLA-A, HLA-B, HLA-C), presenting endogenous antigens to CD8⁺ T cells;
  • Class II (e.g., HLA-DR, HLA-DQ, HLA-DP), presenting exogenous antigens to CD4⁺ T cells;
  • Class III, which includes genes involved in immune function (e.g., components of the complement system) but do not encode classical MHC molecules.

Table 2: Overview of HLA terminology.

TerminologyMeaningExample
HLA genotypeThe exact set of inherited HLA alleles, determined by genetic sequencing. This provides the precise nucleotide sequence of the HLA genes.An individual inherits HLA-DRB1*03:01 from one parent and HLA-DRB1*04:01 from the other. Their HLA genotype is HLA-DRB1*03:01 / HLA-DRB1*04:01.
HLA phenotypeOn an individual level: The set of HLA proteins expressed, determined by the inherited alleles.
In a population: The proportion of individuals expressing a specific HLA protein variant.
Someone with the HLA phenotype HLA-A2 / HLA-B27 expresses these specific HLA proteins on their cells.
HLA allotypeA specific version of an HLA protein that comes from a particular gene variant. Allotypes reflect differences at the protein level, affecting peptide binding and immune responses.HLA-B has different allotypes like HLA-B*27:05 and HLA-B*27:02, which have slight structural differences.
HLA serotypeA way to group HLA proteins based on their reactivity to specific antibodies (serotyping). Serotyping may not differentiate between allelic variants.HLA-A2 is a serotype that includes multiple closely related HLA-A alleles.

In mice, the MHC locus is termed histocompatibility-2 (H-2) complex and is located on chromosome 17. It includes class I (e.g., H-2K, H-2D, H-2L) and class II (e.g., H-2I-A and H-2I-E) molecules (table 3). Similar to humans, mouse MHC I interacts with CD8+ T cells, and mouse MHC II with CD4+ T cells, underscoring the evolutionary conservation of antigen presentation across species.

Table 3: MHC allotypes of frequently used laboratory mouse strains.

MHC Class IMHC Class II
Mouse strainMHC allotypeH-2KH-2DH-2LH-2I-AH-2I-E
C57BL/6 [B6] *bbb-b-
BaLB/cJ [C]dddddd
C3H/HeJ [C3]kkk-kk

* Including the commonly used OT-I mice (C57BL/6-Tg(TcraTcrb)1100Mjb/J), expressing TCRs specific for ovalbumin residues 257–264 on the background of H-2Kb; and OT-2 mice (B6.Cg-Tg(TcraTcrb)425Cbn/J), expressing TCRs specific for ovalbumin residues 323–339 on the background of H-2I-Ab.

1.5 HLA frequency and association with disease

HLA allele frequencies significantly depend on population genetics, leading to great differences between geographic regions. Table 4 shows a global representation of the most frequent HLA variants based on aggregated data by the allele frequency net database (AFND). For example, HLA-A*0201 is one of the most frequent variants in North America and Europe, with phenotype frequencies of 40–50%. HLA-A*2402 represents another frequent variant, with phenotype frequencies of 20–40% in Northeast and Southeast Asia and 15–25% in North America.

Table 4: Globally prevalent HLA class I and II allotypes.

HLA Class I HLA Class II
HLA-A*01:01HLA-DPA1*01:03-DPB1*04:01 (DP401)
HLA-A*02:01HLA-DPA1*01:03-DPB1*04:02 (DP402)
HLA-A*03:01HLA-DQA1*01:01-DQB1*05:01 (DQ5.1)
HLA-A*11:01HLA-DQA1*01:02-DQB1*06:02 (DQ6.2)
HLA-A*24:02HLA-DQA1*02:01-DQB1*02:02 (DQ2.2)
HLA-B*07:02HLA-DQA1*05:01-DQB1*02:01 (DQ2.5)
HLA-B*08:01HLA-DQA1*05:05-DQB1*03:01 (DQ7.5)
HLA-B*35:01HLA-DRA*01:01-DRB1*04:01 (DR4a)
HLA-B*40:01HLA-DRA*01:01-DRB1*15:01 (DR2b)
HLA-B*44:02/B*44:03HLA-DRA*01:01-DRB1*07:01 (DR7a)
HLA-C*04:01HLA-DRA*01:01-DRB1*03:01 (DR3a)
HLA-C*07:01HLA-DRA*01:01-DRB1*13:01/13:02 (DR13a/b)

*Aggregated data provided by AFND (effective Q1/2025).

In line with their enormous genetic diversity and ability to direct T cell responses, certain HLA variants are associated with human susceptibility to diseases (table 5). For instance, HLA-DRB1 variants are strongly associated with rheumatoid arthritis and multiple sclerosis, and with the outcome of infectious diseases like tuberculosis or malaria. Certain HLA-B variants are associated with immune control in human immunodeficiency virus-1 (HIV-1) infection.

Certain HLA-A and HLA-B variants have also been linked to higher susceptibility to cancer. Downregulation of HLA expression is one of the most important evasion mechanisms of tumor cells. While understanding how HLA is linked to disease is crucial, scientists still face major challenges in fully deciphering the complex genetic and environmental interactions that influence these associations.

Table 5: Known associations between HLA variants and human diseases.

 DiseaseHLA variant
InfectionPulmonary tuberculosisHLA-DQB1*0302
MalariaHLA-B53
LeprosyHLA-DRB1*1501
HIV-1 infectionHLA-B*2705
Chronic hepatitis C infectionHLA-DQB1
AutoimmunityMultiple sclerosisHLA-DRB1*1501
PsoriasisHLA-C*06:02
Rheumatoid arthritisHLA-DRB1*0401
Ankylosing spondylitisHLA-B*27
Type 1 diabetes (T1D)HLA-DRB1*0301; DQB1*0302 (DQ8), DQ2
Celiac diseaseHLA-DQA1*0501-DQB1*0201 (DQ2)
NeuropathiesNarcolepsyHLA-DQB1*06:02

2 Analyzing antigen-specific T cells: MHC MACSimer technology

2.1 Principle of MHC MACSimer technology

For flow cytometry staining and sorting of antigen-specific T cells via their TCR, peptide-loaded MHC (pMHC) complexes can be used. When conjugated to a fluorochrome, they enable sensitive detection of rare T cell subsets even from a polyclonal population of T cells. This powerful method is well-established and applicable for basic research and TCR discovery, in-process/quality control in cell manufacturing, and post-infusion research in T cell therapy workflows.

A key challenge in detecting antigen-specific T cells lies in the low affinity of a single TCR for its cognate pMHC complex, typically about 10,000 times lower than the affinity of a conventional antibody for its antigen. To overcome this limitation, TCR avidity becomes a critical factor to detect specific TCRs with pMHC molecules.

Table 6 summarizes and compares TCR affinity, biochemical avidity, and functional T cell avidity, including their definitions, influencing factors, and typical measurement methods.

Table 6: TCR affinity and avidity.

TCR affinityTCR avidity (biochemical)T cell avidity (functional)
DefinitionInteraction strength of one TCR and one pMHC complexInteraction strength of multiple TCRs and coreceptors binding to multiple pMHC complexesT cell responsiveness to a given concentration of a TCR ligand
Mode Single interactionMultiple molecule interactionsT cell activation by a natural or artificial antigen-presenting cell
Influencing factorsMolecular binding strength as defined by the equilibrium dissociation constant (KD)Number of TCR and pMHC molecules, TCR clustering, and coreceptor bindingBiochemical TCR avidity, effector status, T helper subtype, and genetic factors
Measurement methodDetermined by surface plasmon resonance (SPR) analysis of recombinant proteins (PMID: 27252176)Estimated by mean fluorescent intensity (MFI) using MHC multimers (PMID: 23576742)Concentration of a stimulus inducing 50% activation of antigen-specific T cells (PMID: 16818373)

MACS Handbook: MACS Handbook:
Related products Related products:
2.1.1 Increasing TCR binding avidity

For flow cytometry–based detection of TCRs with pMHC molecules, TCR binding avidity is increased by multimerizing several identical pMHC molecules in one construct, enabling the binding of multiple TCRs on one single T cell simultaneously (“multivalency effect”, fig. 2). Conventional multimer technologies such as MHC tetramers use biotinylated pMHC monomers tetramerized on fluorescently tagged streptavidin.

In comparison, MHC MACSimers provide superior TCR avidity and stability, as they carry a precisely balanced number of covalently conjugated pMHCs and fluorochromes on a sterically flexible backbone. Learn more about MHC MACSimer technology, performance, and applications.

Figure 2: Multivalency effect with MHC MACSimers

Detection of rare antigen-specific T cells by linking multiple peptide-MHC complexesarrow leftarrow right

The pMHC molecules of an MHC MACSimer form highly specific and stable complexes with multiple TCRs on the surface of their cognate antigen-specific T cell.

2.2 MHC MACSimer workflows and protocols

MHC MACSimers can be acquired as fully multimerized constructs, either preloaded with peptide (peptide-loaded MHC MACSimers), or in a loadable format (MHC MACSimer FleX Kits). For MHC MACSimer FleX Kit loading, peptide sequences can be chosen from the comprehensive MACSpep Single Peptide portfolio. After sorting of antigen-specific T cells, MHC MACSimer staining is reversible via REAlease® Technology, e.g., for sequential sorting or downstream assays.

Learn more about MHC MACSimer product formats and applications.

Figure 3: MHC MACSimer workflow for flow cytometry–based analysis and sorting of antigen-specific T cells

Illustration showing the fast and easy workflow provided by MHC multimers for T cell receptor staining for flow cytometry analysis or cell sorting.arrow leftarrow right

Peptide-loaded MHC MACSimers form highly specific and stable complexes with the TCR of their cognate T cells and enable antigen-specific T cell analysis on the MACSQuant® Analyzer, or TCR–based cell sorting using the MACSQuant Tyto® Family of cell sorters. For further downstream applications, MHC MACSimers can be gently detached using REAlease Technology.

Table 7: T cell analysis using MHC MACSimers: workflows and protocols.

Detection and analyis
Detection and analysis of antigen-specific T cells using flow cytometry, e.g., for enumeration or phenotypical and functional characterization of T cells and their epitopes.
Preparation of MACSpep single peptides for peptide loading on MHC MACSimers

MHC I MACSimer peptide loading and staining protocol

MHC MACSimer multicolor panel for characterization of T cell maturation
Isolation and sorting
Isolation and sorting of antigen-specific T cells using flow sorting or MACS® Technology, e.g., for enrichment purposes or downstream assays (for expansion, cell culture, TCR sequencing, single-cell sequencing, protein biochemistry, and more).
Sorting of T cells using MHC MACSimers and the MACSQuant Tyto Cell Sorter

Magnetic enrichment of T cells with MHC MACSimers and MACS MicroBeads
Stimulation and expansion
Stimulation of antigen-specific T cells in cell culture using MACSpep Single Peptides, e.g., for expansion against one specific epitope
Preparation of MACSpep single peptides for stimulation and expansion of antigen-specific T cells

3 Designing a successful MHC MACSimer experiment

In order to ensure technical success, there are three important aspects that should be considered before designing an MHC MACSimer experiment: MHC compatibility, peptide selection, and sample preparation.

3.1 MHC allele compatibility

Ensuring compatibility between the MHC allele and the target T cells is essential, as TCRs recognize antigens only when presented by a matching MHC variant.

  • The MHC variant of the MHC MACSimer reagent must match the variant of the intended cell sample. If the MHC variant of a sample is unknown, it can be assessed by different methods:
    • Next-generation sequencing (NGS)
    • HLA typing assays/ kits (qPCR–based)
    • HLA serotyping using flow cytometry (anti-HLA antibodies, e.g., anti-HLA-A2)
  • The MHC MACSimer must match the species of the intended cell sample, as MHC molecules do not cross-react with T cells from different species.

3.2 Peptide selection for loading onto MHC MACSimer FleX Kits

For successful and specific T cell detection with MHC MACSimer FleX Kits, careful peptide selection is critical. Only single peptides are suitable for loading, as peptide pools (e.g., PepTivator® Peptide Pools) containing multiple T cell epitopes compromise TCR binding avidity and are therefore not compatible.

For optimal results with MHC MACSimers, we recommend using our MACSpep Single Peptides portfolio, following the short instructions for MHC MACSimer peptide selection and loading. We offer a wide range of validated epitopes optimized for MHC MACSimer loading and supported by tailored protocols.

Alternatively, lyophilized single-peptide stocks from other sources may also be used, provided they meet key quality and handling requirements.

The following sections guide you through essential considerations for selecting a suitable peptide (3.2.1) and best practices when using peptides from external sources (3.2.2) to achieve optimal loading efficiency.

3.2.1 Single peptide selection

There are three major considerations for selecting a suitable MHC peptide:

  • Define your T cell epitope: Ensure the selected peptide is restricted to your MHC of interest, as each MHC variant naturally binds distinct peptide sequences. You can identify suitable epitopes using:
  • Determine MHC binding affinity: The peptide must have sufficient molecular binding affinity to the MHC type of interest, or it cannot be loaded. Use online tools such as NetMHCpan to calculate the affinity.
  • Ensure solubility*: The peptide must be soluble in aqueous solution. Use GRAVY calculators to assess the hydrophobicity of your peptide, and test solubility by dissolving a sample of the peptide in buffer before preparing the final MHC loading reaction (watch out for cloudiness and precipitation).

*Important note: Some peptides are highly hydrophobic due to their amino acid composition, which can make manual loading challenging or impractical. For these specific cases, we recommend using peptide-loaded MHC MACSimers . A list of these sequences is provided in the protocol for the preparation of MACSpep Single Peptides for peptide loading on MHC MACSimers.

3.2.2 Important recommendations when using single peptides from other sources

Lyophilized single-peptide stocks from other sources may be used as well. In such cases, it is essential to follow the guidelines below to achieve successful loading and performance:

  • Dissolve peptides in accurately weighable amounts (≥1 µg). If precise weighing isn’t possible (e.g., no access to a microscale), use the entire lyophilized stock to ensure an exact peptide concentration.
  • Determining peptide concentration in liquid phase is not recommended; instead, always calculate concentration based on the weight of the lyophilized peptide and the volume of the solvent used.
  • Dissolve peptides in DMSO, as the solubility of peptides in water or buffer might be limited.
  • Dissolve peptide to a stock concentration of 10 mmol/L or higher, as smaller dilution series from a higher concentrated stock are recommended for titration of the optimal peptide loading concentration.
  • Rule out precipitation of the peptide in your dilution series (apparent by pellet formation and/or clouding). If precipitation is observed, consider increasing DMSO rate or decreasing peptide concentration.
  • Dissolve peptide under sterile conditions if considering using it in cell culture applications.
  • Peptides containing cysteines might need to be reduced with 10 mmol/L DTT for 30 minutes at room temperature before use (if stored at –20 °C a longer period might be necessary).

3.3 Sample source and preparation

MHC MACSimers are compatible with a wide range of sample types, including whole blood, PBMCs (isolated by density-gradient centrifugation), and preenriched or isolated T cells.

If magnetic preenrichment of T cells is required, we recommend using the negative isolation kits listed below. These kits deplete unwanted cell populations while leaving target T cells untouched and unlabeled, preserving TCR and coreceptor integrity for reliable posterior MHC MACSimer staining.

Important note: Avoid positive selection via CD4 or CD8 coreceptors, as direct labeling of these markers can interfere with TCR accessibility due to their close spatial proximity, potentially compromising MHC MACSimer staining.

Related products Related products:
3.3.1 How to prepare a cell sample for MHC MACSimer staining

T cell characteristics and origin significantly influence MHC MACSimer staining efficiency. The relative frequency of TCR-expressing cells in a sample, as well as the expression levels of surface TCRs, are decisive factors for the technical success of the staining. To ensure reliable and specific staining of antigen-specific T cells, consider the following factors when preparing your cell sample:

  • Viability: T cells should be fresh or properly cryopreserved to maintain viability and TCR integrity. Viability should be tested before staining.
  • TCR internalization: In response to peptide–based stimulation, antigen-specific T cells internalize their TCRs, making them temporarily undetectable by MHC MACSimers. Allow a resting phase of 5–7 days post-stimulation to enable TCR re-expression on the cell surface (see chapter 4.1., fig. 4).
  • Fixation compatibility: Fixation protocols may affect TCR conformation and multimer binding. Test your fixation method for every specific application, e.g., by comparing staining results from fixed and unfixed samples to ensure compatibility with your workflow.
  • Target cell frequency: The frequency of target cells in your sample should exceed the detection threshold of MHC MACSimer technology for reliable results. When analyzing ultra-rare T cells, increase the number of cells stained and events acquired by flow cytometry. Include proper negative controls to exclude the background signal.

4 Expert tips and experiment optimization

4.1 Peptide pools vs. single peptides for T cell expansion

Antigen-specific T cells can be expanded using either peptide pools (e.g., PepTivator Peptide Pools) or defined single-peptide epitopes (e.g., MACSpep Single Peptides), applied before or after MHC MACSimer staining or isolation. Table 9 outlines key differences between both approaches to help you select the most suitable method for your experiment.

Importantly, T cells typically internalize their TCRs following peptide stimulation. To allow for effective MHC MACSimer staining, expanded cells should undergo a resting phase of 5–7 days in culture to enable TCR re-expression (fig. 4).

Table 9: Functional differences between peptide pools and single peptides in T cell assays.

 PepTivator Peptide PoolsMACSpep Single Peptides
FormatPeptide poolSingle peptides
Peptide length15-mers with 11 amino-acid overlaps, covering full protein sequences.
Specific T cell epitopes with a defined length (8–12-mer for MHC class I, 13–25-mer for MHC class II).
Sequence coverageCovering multiple peptide sequences.Single defined epitope, restricted to bind either an MHC I or MHC II molecule.
Main applicationsQuick and robust activation and expansion of antigen-specific CD4+ and CD8+ T cells for functional assays (e.g., cytokine secretion assays, proliferation, T cell enrichment).
Validated for use with rapid ARTE protocol for T cell enrichment and analysis.
Epitope-specific stimulation and expansion of T cell populations in cell culture, e.g., before MHC multimer staining.
T cell expansion propertiesBroad expansion: stimulates diverse T cell populations (multiple peptide-MHC combinations).Narrow expansion: stimulates only one T cell specificity (one peptide-MHC combination).
T cell tracking Tracks multiple T cell populations with different TCR specificities.Tracks a single epitope-specific T cell population.

4.1.1 Epitope-specific expansion protocol using MACSpep Single Peptides

The following protocol provides a general framework for expanding antigen-specific T cells from PBMCs using MACSpep Single Peptides. Please note that expansion efficiency can vary significantly depending on donor, HLA type, and T cell epitope. Optimization may be required to achieve optimal results.

Cell culture conditions: To expand antigen-specific T cells, such as human cytomegalovirus (CMV) pp65-reactive CD8⁺ T cells, PBMCs should be cultured at a density of 1×10⁷ cells/mL in TexMACS™ Medium supplemented with 5% human serum albumin (or an alternative suitable culture medium).

Day 0: Add the single peptide of choice (e.g., MACSpep CMV pp65, NLVPMVATV) to a final concentration of 1 nmol/mL. Incubate cells at 37 °C and 5% CO₂.

Day 2: Replace the culture medium with fresh medium containing 50 U/mL of Interleukin-2 (IL-2).

From day 3: Monitor cells daily to ensure nutrient levels remain sufficient. Based on cell density and expansion kinetics, fresh medium may be added every 2–3 days. Additional cytokines can be added as needed, depending on the experimental setup and application.

Figure 4: MHC MACSimer staining of antigen-specific T cells expanded with MACSpep Single Peptides, highlighting TCR internalization and re-expression effect.

Dot plots showing flow cytometry analysis of antigen-specific T cells before and after 3, 5, and 7 days of expansion with MACSpep single peptides. T cells were stained with MHC multimers.arrow leftarrow right

PBMCs were cultured at a concentration of 1×107 cells/mL in TexMACS Medium supplemented with 5% human serum albumin. At day 0, they were stimulated once with 1 nmol/mL MACSpep CMV pp65 (NLVPMVATV), HLA-A*02. On day 2, fresh medium was added containing 50 units of recombinant human IL-2. Subsequently, fresh culture medium was supplemented every 2–3 days. MHC MACSimer stainings at day 0, 3, 5, and 7 were performed using MHC MACSimer A*0201 CMV pp65 (NLVPMVATV), human, Vio R667, according to the standard MHC MACSimer staining protocol. On measurement day 3, TCR internalization is apparent by significant reduction in the frequency of TCR+ T cells in the cell culture (from 0.55% to 0.04% among CD8+ cells). Starting from day 5, TCRs are re-expressed. CD8-FITC costaining was performed using CD8 Antibody, anti-human, REAfinity. Flow cytometry analyses were done using the MACSQuant Analyzer.

4.2 MHC allele–specific titration for optimal staining performance

The optimal staining performance of MHC MACSimers can vary depending on the specific peptide–MHC (pMHC) complex and the corresponding TCR avidity. While the standard staining protocol recommends a concentration of 36–60 nM (as given by standard staining protocol), certain MHC alleles may require adjustment to avoid suboptimal or non-specific binding. For example, HLA-B*3501 and HLA-A*1101 can exhibit non-specific over-titration effects at 36 nM (fig. 5). Therefore, we recommend empirically determining the optimal concentration for each MHC allele through titration.

Figure 5: MHC allele–specific titration effects on MHC MACSimer staining.

Dot plots showing flow cytometry analysis of antigen-specific T cells stained with different concentrations of MHC multimers, with respective percentage of target cells, median fluorescence, and stain index for each concentration.arrow leftarrow right

Titration of MHC MACSimers reveals allele-specific differences in staining performance across distinct MHC alleles. Optimal concentrations vary by allele, highlighting the importance of empirical titration for each variant. Human HLA-A*0101 CMV pp50-, B*3501 EBV BZLF1-, and A*1101 EBV EBNA3B-reactive CD8+ T cells from healthy donors were expanded and spiked into PBMCs. Cells were stained using MHC MACSimer FleX Kits loaded with the respective CMV and EBV antigens. Starting from a final MHC MACSimer concentration of 36 nM (according to the standard staining protocol), MHC MACSimer concentration was titrated down to 1 nM. For every tested concentration, frequency, PE-median, and stain index (SI) of MHC MACSimer+ cells are shown. CD8-FITC costaining was performed using CD8 Antibody, anti-human, REAfinity (REA734). Flow cytometry analyses were done using the MACSQuant Analyzer.

4.3 Optimizing the efficiency of REAlease Technology on MHC MACSimers

The efficiency of REAlease Technology on MHC MACSimers after flow staining and sorting depends on several factors. To achieve optimal results, please consider the following recommendations:

  • Using Anti-PE MACS MicroBeads for magnetic enrichment of MHC MACSimer+ T cells blocks the REAlease reagent. Therefore, REAlease Technology is effective only in the context of flow cytometry.
  • Not all MHC MACSimer variants are releasable. Check the product data sheet to confirm whether the “release feature” is available. Releasability is defined as achieving at least a 90% reduction in mean fluorescence intensity (MFI) following the REAlease protocol, which corresponds to freeing 90% or more of TCRs from staining.
  • REAlease efficiency is highest with Vio R667–labeled MHC MACSimers, due to the dye’s biochemical and molecular properties. For complete optical release, we recommend using Vio R667-labeled reagents.
  • Avoid incubating MHC MACSimers at temperatures above 2–8 °C if you plan to release the staining afterward. Incubation at room temperature may impair release due to accelerated TCR internalization.
  • Expanded or stimulated T cells often show increased TCR internalization, which can reduce the efficiency of the release.

Related products Related products:

4.4 Antibody clone compatibility

MHC MACSimers are compatible with multicolor flow cytometry. For costaining of CD8+ or CD4+ antigen-specific T cells with MHC MACSimers, the following standard antibody panel is recommended to achieve optimal performance and clear signal resolution (table 10).

Table 10: Standard panel for antigen-specific T cell analysis in combination with MHC MACSimers.

SpecificityCloneGatingFluorochromeDetection channel (nm)Titer
ViobilityTM 405/520 Fixable Dye-Live/dead discrimination405/520525/50 (violet)1:100
CD14REA599Detection of macrophages and monocytesVioGreen™525/50 (violet)1:50
CD20*LT20Detection of B cells and dendritic cellsVioGreen525/50 (violet)1:50
*Or instead CD19REA675Detection of B cells and dendritic cellsVioGreen525/50 (violet)1:50
CD3REA613Detection of T cellsPE-Vio 770785/62 (blue)
1:50
CD4REA623Detection of helper T cellsAPC-Vio 770785/62 (red)
1:100
CD8REA734Detection of cytotoxic T cellsVio Bright V600615/20 (violet)1:100
MHC class I or II MACSimer-PE-TCR stainingPE585/40 (blue)
 
MHC class I or II MACSimer-Vio R667-TCR stainingVio R667667/30 (red)
 

Importantly, some CD8 and CD4 antibody clones can interfere with pMHC–TCR binding, reducing MHC MACSimer staining efficiency. This interference occurs because CD8 and CD4 coreceptors are positioned very close to the TCR and play an essential role in stabilizing the pMHC–TCR interaction during T cell activation. As a result, some antibody clones targeting these coreceptors can sterically hinder or disrupt this binding, leading to reduced staining efficiency of MHC MACSimers. Table 11 lists antibody clones that have been thoroughly tested and verified to be compatible with MHC MACSimers, providing accurate and reliable detection of antigen-specific T cells.

Table 11: Validated antibody clones for coreceptor staining with MHC MACSimers.

AntibodyClone
CD8 Antibody, anti-human, REAfinityREA734
CD8a Antibody, anti-mouse, REAfinityREA601
CD8a Antibody, anti-mouse, REAfinity53-6.7
CD4 Antibody, anti-human, REAfinityREA623

4.5 Increasing detection of ultra-rare T cells using the FASER Signal Amplification Kit

While MHC MACSimers provide high sensitivity, detecting ultra-rare T cell populations may require further signal enhancement. The fluorescence amplification by sequential employment of reagents (FASER) kit boosts low fluorescence signals to improve detection accuracy.

The FASER-PE kit works by sequentially adding a PE-specific activator followed by a fluorochrome-conjugated enhancer. The activator binds to the PE-labeled MHC MACSimer, and the enhancer attaches to the activator, amplifying the fluorescence intensity. This amplification cycle can be repeated multiple times to significantly increase signal intensity (fig. 6).

Please note that REAlease Technology, which allows antibody removal after staining, is incompatible with FASER-amplified samples.

Figure 6: Signal enhancement of EBV-specific CD8⁺ T cells using FASER amplification with MHC MACSimers.

Dot plots and bar graph from flow cytometry analysis of antigen-specific T cells, comparing the percentage of target cells, median fluorescence, and stain index between cells stained with a standard protocol for MHC multimers or cells stained with MHC multimers and FASER amplification method.arrow leftarrow right

FASER amplification significantly enhances the detection sensitivity of ultra-rare antigen-specific T cells by increasing signal intensity and stain index, enabling more reliable identification of rare populations. A: Human HLA-A*2402+ EBV-reactive CD8+ T cells from a healthy donor were expanded and spiked into PBMCs. Cells were stained using the MHC MACSimer A*2402 EBV LMP2a (PYLFWLAAI), human, PE, according to standard staining protocol (left plot). In addition, two rounds of FASER amplification were tested (right plot). B. The column graph compares frequency, PE-median, and stain index (SI) of MHC MACSimer+ cells between standard staining, 1x FASER amplification, and 2x FASER amplification. CD8-FITC costaining was performed using CD8 Antibody, anti-human, REAfinity (REA734). Flow cytometry analyses were done using the MACSQuant Analyzer.

4.6 Increasing signal confidence with duplex staining using MHC MACSimers

Staining cells with two MHC MACSimers of identical specificity but conjugated to different fluorochromes, a technique known as duplexing, offers two key advantages for the detection of antigen-specific T cells:

  • Increased signal confidence: Using two differently labeled MHC MACSimers targeting the same antigen-specific TCR reduces the risk of false-positive events caused by background noise or gating errors.
  • Robust validation of TCR-pMHC specificity: Using two different conjugates with the same TCR specificity can confirm that the interaction is biologically specific and not due to fluorophore- or batch-related artifacts. Only double-positive events indicate antigen-specific T cells. A specific duplex signal typically appears as a diagonal population, reflecting the affinity of both reagents for the same TCR (fig. 7).

Figure 7: Improved specificity in antigen-specific T cell detection using duplex MHC MACSimer staining.

Dot plots showing flow cytometry analysis of antigen-specific T cells stained with MHC multimers, comparing the percentage of target cells between single and duplex staining.arrow leftarrow right

Murine H-2Kb+ ovalbumin (OVA)−reactive OT1 splenocytes were spiked into C57BL/6J splenocytes. Cells were stained using the MHC MACSimer H-2Kb ovalbumin (SIINFEKL), mouse, according to the standard staining protocol. Cells were single-stained with Vio R667-conjugated MACSimer only (left plot), or double-stained with Vio 667- and PE-conjugated MACSimer simultaneously (duplex, right plot). Flow cytometry analyses were done using the MACSQuant Analyzer.

4.7 Multiplexing for epitope screening

For large-scale epitope screening, multiplexing can be beneficial, especially when working with limited cell material. This approach allows simultaneous testing of multiple MHC allele variants and/or peptide sequences within a single sample. MHC MACSimers are compatible with multiplexing; however, careful experimental design is essential to avoid potential pitfalls:

  • Multiplexing with peptide-loaded MHC MACSimers: Preloaded MHC MACSimers of different MHC variants and/or peptide sequences can be combined to stain one sample simultaneously. Notably, when selecting the same fluorochrome for multiple MHC variants and/or peptide sequences, it is not possible to assign the resulting fluorescent signal to one of these variants. If this distinction is desired, we recommend choosing different fluorochrome conjugates.
  • Multiplexing with MHC MACSimer FleX Kits: When multiplexing different peptide sequences restricted to one or more MHC allele variants using the MHC MACSimer FleX Kit, each peptide loading reaction must be carried out separately for each specificity. Before combining the loaded MHC MACSimers in one sample, each must be individually purified, e.g., via spin column purification. This step is essential, as cross-loading of peptides due to overlapping binding affinities cannot be ruled out, even between different MHC variants.

5 Troubleshooting guide

If your T cell staining shows no signal or unusually high background when using MHC MACSimers, please refer to the questions in table 12 as a diagnostic tool to identify potential issues. This troubleshooting guide outlines key factors that may influence staining quality, from sample preparation to data analysis, and is designed to support you in optimizing your workflow.

If you’ve gone through the list and still can’t identify a potential source of error, don’t hesitate to reach out to our technical support team – we’re here to help.

Table 12: MHC MACSimer troubleshooting guide

1. Sample preparation, staining, MHC compatibility
Are your cells healthy and expressing surface TCRs?Cells should be viable and healthy before staining. If they've been expanded or stimulated, they may have internalized TCRs. In this case, a resting phase of 5 to 7 days is recommended before staining.
Does your T cell sample express the MHC allotype that matches the MHC MACSimers?MHC MACSimers must match the MHC allotype your cells are restricted to. Binding won’t occur if there’s a mismatch, even within the same species.
How was your T cell epitope selected, and do your T cells still reflect the intended specificity?Ensure that your epitope is well-defined, ideally registered in an immune epitope database (e.g., IEDB) or described in peer-reviewed literature. If you're working with expanded T cells or T cells transduced with a specific TCR, confirm that the population still reflects the intended specificity. Be aware that enrichment methods, especially those using peptide pools, can sometimes skew the TCR repertoire toward off-target pMHC combinations.
Did recent stimulation or expansion cause TCR internalization, reducing multimer binding?
Expanded/stimulated T cells internalize their TCRs and need 5 to 7 days resting in culture to re-express their surface TCRs and enable proper TCR staining.
Is your antibody panel compatible with MHC MACSimers?Some antibody clones used for CD8/CD4 coreceptor staining may interfere with MHC multimer binding. Compatibility with MHC multimers must be tested.
Is your fixation method compatible with MHC MACSimers?Fixation can compromise TCR integrity. Always assess the compatibility of your fixation method for your specific application, e.g., by comparing staining results from fixed and non-fixed samples.
Is the frequency of antigen-specific T cells in your sample sufficient for detection?Rare populations may fall below the detection threshold. Detection sensitivity depends on the MHC allele, peptide, and type of T cell sample. For ultra-rare T cells, increase the number of stained cells and acquired events, and use appropriate negative controls to exclude background. With optimized protocols, MHC MACSimers have detected as few as 0.02% antigen-specific cells within the CD3⁺CD8⁺ population of PBMCs.
Was the number of PBMCs used adequate for reliable detection?
Low cell input can lead to increased background noise. For PBMCs, we recommend a minimum concentration of 2×107 cells/mL (equivalent to 1×106 cells in 55 µL for the standard MHC MACSimer protocol). Note that optimal cell numbers may differ for other T cell sample types, such as TCR-transduced lines or expanded T cells.
2. MHC MACSimer handling and staining conditions
Have the MHC MACSimers been stored and handled appropriately?MHC Class I MACSimers must be stored at 2–8 °C protected from light. Please refer to the vial label for the expiration date. The shelf-life of the MHC MACSimer FleX Reagent after peptide loading varies significantly depending on the specific pMHC combination. As a result, a general post-loading expiration period cannot be provided.
Have the MHC MACSimers been centrifuged before staining?
A colorful pellet after centrifugation at 3300×g for 5 minutes indicates precipitation of the pMHC complex, which can interfere with staining performance.
Was the staining time and concentration optimized for the experiment?TCR-binding affinity and avidity of every pMHC combination vary depending on allele, peptide sequence, and T cell sample. Titration of the optimal staining concentration before experimental setup is essential to technical success.
Were there washing steps included between staining steps?Washing between the fluorescent staining steps and before measurement reduces background noise and improves signal resolution.
Have the staining conditions been optimized?We recommend optimizing MHC MACSimer staining conditions for every application. Longer incubation times (20 minutes instead of 10 minutes) or higher staining temperatures (room temperature instead of 2–8 °C) can improve staining performance for certain types of T cells.
3. Experimental controls
Were the necessary positive and negative controls included?Controls are essential for the accurate detection of target cell populations. Include both types when possible to guide analysis and gating. See chapter 4 of the MHC MACSimer staining protocol for more details on recommended staining control strategies.
4. Flow cytometry setup and analysis
Is the flow cytometer calibrated?Proper instrument calibration is a prerequisite to technical success.
Have compensation controls been set up?Use single-stained controls and verify settings for each fluorophore used. Check that fluorescence spillover is appropriately corrected. Inadequate compensation can lead to missed detection of rare T cell populations or misinterpretation of background signals.
Has my antibody panel been optimized?Professional panel design is essential when working with rare antigen-specific T cells. Refer to our panel building resources and the panel builder tool for help.
Are gating strategies in place to isolate the T cell population?Accurate gating improves data quality. We recommend the following strategy:
1) Exclusion of singlets and selection of live lymphocytes;
2) Exclusion of B cells and monocytes;
3) Positive selection of CD3+ T cells and CD8+ or CD4+ T cells;
4) Within the T cell population, MHC MACSimers should be gated using the appropriate gating controls.
Has the fluorescence minus one (FMO) control been used?FMO controls help define gating boundaries and reduce the risk of false positives, especially for rare populations.

To further optimize your MHC MACSimer workflows, we recommend consulting the following scientific resources:

  • Wooldridge L. et al. (2009) Immunology 126(2):147-64. | Read article
  • Chang J. (2021) Mol Cells 44(5):328-334. | Read article
  • Dolton G., Tungatt K. et al. (2015) Immunology 146(1):11-22. | Read article

You have previously chosen International as your location.
What do you want to do?